CoChat
Sign Up
Cited by 410Diabetes Management and ResearchDiabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patients

The DOI matches its Crossref record; 78 of the 80 references it cites were found in a registry or an index.

Glucose Variability; Does It Matter?

Siegelaar, Sarah E., Holleman, Frits, Hoekstra, Joost B. L., DeVries, J. Hans·2010·Endocrine Reviews
DOI 10.1210/er.2009-0021
Open this paper in CoChat — free account

Abstract

Overall lowering of glucose is of pivotal importance in the treatment of diabetes, with proven beneficial effects on microvascular and macrovascular outcomes. Still, patients with similar glycosylated hemoglobin levels and mean glucose values can have markedly different daily glucose excursions. The role of this glucose variability in pathophysiological pathways is the subject of debate. It is strongly related to oxidative stress in in vitro, animal, and human studies in an experimental setting. However, in real-life human studies including type 1 and type 2 diabetes patients, there is neither a reproducible relation with oxidative stress nor a correlation between short-term glucose variability and retinopathy, nephropathy, or neuropathy. On the other hand, there is some evidence that long-term glycemic variability might be related to microvascular complications in type 1 and type 2 diabetes. Regarding mortality, a convincing relationship with short-term glucose variability has only been demonstrated in nondiabetic, critically ill patients. Also, glucose variability may have a role in the prediction of severe hypoglycemia. In this review, we first provide an overview of the various methods to measure glucose variability. Second, we review current literature regarding glucose variability and its relation to oxidative stress, long-term diabetic complications, and hypoglycemia. Finally, we make recommendations on whether and how to target glucose variability, concluding that at present we lack both the compelling evidence and the means to target glucose variability separately from all efforts to lower mean glucose while avoiding hypoglycemia.

Overview

Integrity signals

Registry

Crossref · 10.1210/er.2009-0021

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 80 references

Research works printed but not linked: 2

  1. Bugler J, Buell H 2008 Measuring glycemic variability—an estimation of data required based on a 90 day user study. Proc of 27th Workshop of the Artificial Insulin Delivery/Pancreas and Islet Transplantation study group of the European Association for the Study of Diabetes, Innsbruck, Austria, 2008 (Abstract S16)
  2. Devos, 2007, Impact of tight glucose control by intensive insulin therapy on ICU mortality and the rate of hypoglycemia: final results of the Glucontrol study, Intensive Care Med, 33, S189

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Siegelaar, S. E., Holleman, F., Hoekstra, J. B. L., & DeVries, J. H.
Affiliations
Amsterdam UMC Location University of Amsterdam (NL)
Corresponding author
Siegelaar, Sarah E.
ORCID
Venue
Endocrine Reviews
Publisher
The Endocrine Society
Published
2010-04-01
Volume
31
Issue
2
Pages
171-182
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
DOI
10.1210/er.2009-0021
OpenAlex
W2100202103
Cited by
409
References
80
Citations by year
2026: 6 · 2025: 10 · 2024: 11 · 2023: 13 · 2022: 28 · 2021: 25 · 2020: 25 · 2019: 30 · 2018: 30 · 2017: 25 · 2016: 26 · 2015: 33 · 2014: 40 · 2013: 37 · 2012: 30
FWCI
4.79
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
Keywords
glycemic variability, type 1 diabetes, type 2 diabetes, oxidative stress, microvascular complications, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, hypoglycemia, glycemic control, HbA1c, glycemic excursions, mortality
MeSH terms
Animals, Blood Glucose, Diabetes Mellitus, Humans, Hypoglycemia, Insulin, Blood Glucose Self-Monitoring, Oxidative Stress, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review